Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving anti-HCV therapy.

Stanislas Pol1, Vincent O Mallet

  • 1Université Paris Descartes; APHP, Hôpital Cochin, Hépatologie; INSERM U. 567, Institut Cochin; Paris, France. stanislas.pol@cch.aphp.fr

Discovery Medicine
|January 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diagnostic approach for metabolic dysfunction associated steatotic liver disease].

La Revue du praticien·2026
Same author

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis.

Infectious diseases and therapy·2026
Same author

HCV Cure: To Bridge the Gaps in the Care Continuum.

Journal of viral hepatitis·2026
Same author

In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus.

Cell reports·2025
Same author

Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor.

JHEP reports : innovation in hepatology·2025
Same author

Mortality risk in migrant and non-migrant individuals with chronic hepatitis B virus infection: a French hospital-based cohort study (ANRS CO22 HEPATHER).

BMC global and public health·2025
Same journal

Cannabis and Cannabidiol, GLP-1 Receptors, and Autophagy: The Burgeoning Link Between Cognitive Neurodegeneration With Alzheimer's Disease and Metabolic Disorders.

Discovery medicine·2026
Same journal

The Urgent Need to Assess and Prevent the Deposits of Microplastics and Nanoplastics in Our Brain.

Discovery medicine·2025
Same journal

Bridging the Translational Gap: Prioritizing the Spontaneous Canine Osteoarthritis Model for Preclinical Studies.

Discovery medicine·2025
Same journal

Harnessing the Power of Chlorogenic Acid: Inhibiting IL-2-Mediated Treg Upregulation to Combat Post-Traumatic Osteomyelitis.

Discovery medicine·2025
Same journal

The Relationship of <i>MAPK10P</i> Gene Polymorphism With P-Wave Peak Time and P-Wave Dispersion in Elderly Patients With Paroxysmal Atrial Fibrillation.

Discovery medicine·2025
Same journal

Curcumin Attenuates PD-L1-Positive Neutrophil-Induced T-Lymphocyte Apoptosis and Alleviates Lung Injury During Sepsis in Rats.

Discovery medicine·2025
See all related articles

Hepatitis C virus (HCV) infection affects millions globally. Optimizing interferon and ribavirin treatment doses and duration is crucial for improving patient outcomes and reducing disease impact.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection impacts approximately 123 million people worldwide, representing about 2% of the global population.
  • HCV infection leads to significant morbidity and mortality.
  • The combination therapy of interferon and ribavirin is a recognized treatment for HCV.

Purpose of the Study:

  • To investigate the impact of treatment parameters on Hepatitis C virus (HCV) outcomes.
  • To determine optimal dosing and duration strategies for interferon and ribavirin therapy.

Main Methods:

  • This study focuses on analyzing treatment outcomes based on varying doses and durations of interferon and ribavirin.
  • Statistical analysis of patient data to correlate treatment regimens with efficacy.

Related Experiment Videos

Main Results:

  • Treatment outcomes for Hepatitis C virus (HCV) are significantly influenced by the specific doses and duration of interferon and ribavirin used.
  • Variations in treatment protocols directly correlate with patient response rates and overall effectiveness.

Conclusions:

  • Optimizing the dosage and duration of interferon and ribavirin therapy is essential for maximizing treatment success in Hepatitis C virus (HCV) patients.
  • Further research into personalized treatment strategies for HCV is warranted to improve patient prognoses.